JPMorgan Chase & Co. Reduces Holdings in Inhibrx, Inc. (NASDAQ:INBX)

JPMorgan Chase & Co. lowered its holdings in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 88.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,135 shares of the company's stock after selling 39,130 shares during the period. JPMorgan Chase & Co.'s holdings in Inhibrx were worth $80,000 at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Insider Activity

In other news, Director Jon Faiz Kayyem acquired 69,686 shares of the firm's stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average cost of $14.23 per share, for a total transaction of $991,631.78. Following the acquisition, the director now directly owns 51,093 shares in the company, valued at approximately $727,053.39. The trade was a -374.80 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 22.20% of the company's stock.

Inhibrx Stock Down 2.7 %

NASDAQ:INBX traded down $0.35 during trading hours on Friday, reaching $12.60. 75,504 shares of the company traded hands, compared to its average volume of 94,568. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $18.95. The business's 50-day moving average price is $14.30 and its two-hundred day moving average price is $14.61.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.